Your browser is no longer supported. Please, upgrade your browser.
Jasper Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own25.70% Shs Outstand12.50M Perf Week-3.99%
Market Cap394.19M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month33.33%
Income-4.30M PEG- EPS next Q- Inst Own57.10% Short Float- Perf Quarter42.86%
Sales- P/S- EPS this Y-986.70% Inst Trans298.97% Short Ratio0.04 Perf Half Y43.15%
Book/sh6.90 P/B2.06 EPS next Y- ROA-4.30% Target Price- Perf Year43.29%
Cash/sh0.01 P/C1313.97 EPS next 5Y- ROE-4.80% 52W Range7.11 - 18.88 Perf YTD41.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.82% Beta-
Dividend %- Quick Ratio1.30 Sales past 5Y- Gross Margin- 52W Low86.36% ATR2.58
Employees24 Current Ratio1.30 Sales Q/Q- Oper. Margin- RSI (14)55.46 Volatility20.83% 28.74%
OptionableNo Debt/Eq0.00 EPS Q/Q-4.00% Profit Margin- Rel Volume0.26 Prev Close14.20
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.72M Price13.25
Recom- SMA2018.08% SMA5026.35% SMA20030.52% Volume715,005 Change-6.69%
Oct-21-21Initiated William Blair Outperform
Oct-20-21Initiated BMO Capital Markets Outperform $19
Oct-13-21Initiated Oppenheimer Outperform $21
Oct-15-21 09:39PM  
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.